Edwards Lifesciences Corporation focuses on technologies that treat structural heart disease and critically ill patients worldwide. The company offers products and technologies to treat advanced cardiovascular disease. These are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy, and Critical Care. Transcatheter Heart Valve Therapy The company offers its transcatheter heart valves to patients. As of December 31, 2014, its transcatheter aortic heart valves were available for sale in approximately 65 countries. Surgical Heart Valve Therapy The core of the company’s surgical tissue heart valve product line is the Carpentier-Edwards PERIMOUNT pericardial valve, including the line of PERIMOUNT Magna Ease valves, the newest generation pericardial valves for aortic and mitral surgical replacement. With significant clinical data on durability and performance, PERIMOUNT valves are the most widely prescribed tissue heart valves in the world. The company developed the EDWARDS INTUITY Valve System. The company offers protection cannulae, which are used during cardiac surgery. Critical Care The company offers hemodynamic monitoring systems used to measure a patient's heart function in surgical and intensive care settings. The company’s hemodynamic monitoring technologies are used before, during, and after surgeries, such as open-heart, major vascular, major abdominal, neurological, and orthopedic surgical procedures, as well as for acutely ill patients with conditions, such as sepsis, acute respiratory distress syndrome, and multi-organ failure. The company manufactures products to help clinicians make more informed fluid management decisions for their patients, including the minimally invasive FloTrac continuous cardiac output monitoring system, and the non-invasive ClearSight hemodynamic monitor that provides real-time, beat-to-beat information. Its hemodynamic monitoring product line also includes the Swan-Ganz line of pulmonary artery catheters, the PreSep continuous venous oximetry catheter for measuring central venous oxygen saturation, and the VolumeView sensor-catheter set that measures a critically ill patient's volumetric hemodynamic parameters. The company’s EV1000 clinical monitoring platform displays a patient's physiologic status and integrates many of its sensors and catheters into one intuitive platform. The company manufactures and sells various peripheral vascular products used to treat endolumenal occlusive disease, including the Fogarty line of embolectomy catheters. Sales and Marketing The company’s portfolio includes some of the most recognizable product brands in cardiovascular devices. In the United States, it sells substantially all of its products through its direct sales force. In 2014, 55% of the company’s reported sales were derived internationally through its direct sales force and independent distributors. Of the total international sales, 58% were in Europe, 20% were in Japan, and 22% were in Rest of World. The company sells its products in approximately 100 countries, and its major international markets include Australia, Brazil, Canada, France, Germany, Italy, Japan, the Netherlands, Spain, and the United Kingdom. Research and Development For the year ended December 31, 2014, the company invested $346.5 million on research and development. Proprietary Technology The company owns approximately 2,500 issued United States patents, pending United States patent applications, issued foreign patents, and pending foreign patent applications. It also owns or has rights in United States and foreign patents and patent applications in the field of transcatheter heart valve repair and replacement. In addition, the company owns or has rights in United States and foreign patents and patent applications that cover catheters, systems and methods for hemodynamic monitoring, and vascular access products. Competition In Surgical and Transcatheter Heart Valve therapies, the company’s primary competitors include Medtronic, Inc.; St. Jude Medical, Inc.; and Sorin Group. In Critical Care, it competes primarily with various companies in specific product lines, including ICU Medical, Inc.; PULSION Medical Systems SE, a subsidiary of Getinge AB; and LiDCO Group PLC. Government Regulation and Other Matters The company’s products and facilities are subject to regulation by various government agencies, including the U.S. Food and Drug Administration, European Community Notified Bodies, and the Japanese Pharmaceuticals and Medical Devices Agency, to confirm compliance to the various laws and regulations governing the development, testing, manufacturing, labeling, marketing, and distribution of its products. The company is also subject to additional laws and regulations that govern its business operations, products, and technologies, including the Stark law; the Physician Payments Sunshine Act; the False Claims Act; and the United States Foreign Corrupt Practices Act. History Edwards Lifesciences Corporation was founded in 1999. The company was incorporated in Delaware in 1999.
edwards lifesciences corp (EWL:Berlin)
One Edwards Way
Irvine, CA 92614
|Cerner Corp||$55.31 USD||-3.18|
|CR Bard Inc||$182.91 USD||-4.22|
|Endo International PLC||$53.87 USD||-0.43|
|Intuitive Surgical Inc||$536.24 USD||-15.69|
|Smith & Nephew PLC||1,093 GBp||-8.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact EDWARDS LIFESCIENCES CORP, please visit www.edwards.com. Company data is provided by Capital IQ. Please use this form to report any data issues.